Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

FDA Drug Recalls

17 recalls · Class II, newest first

Class II · Moderate risk

Gordofilm Wart Remover

cGMP Deviations

Completed cGMP deviation Dercher Enterprises, Inc., DBA Gordon Laboratories NDC 10481-3009-01 D-0495-2024
Class II · Moderate risk

AstrinGyn (Ferric Subsulfate)

CGMP Deviations: Products not manufactured under current good manufacturing practices.

Completed cGMP deviation Ecometics, Inc. NDC 59365-6065-0 D-1101-2023
Class II · Moderate risk

activator concentrate

CGMP Deviations: Products not manufactured under current good manufacturing practices.

Completed cGMP deviation Ecometics, Inc. D-1100-2023
Class II · Moderate risk

Unguentine Ointment

CGMP Deviations: Products not manufactured under current good manufacturing practices.

Completed cGMP deviation Ecometics, Inc. D-1099-2023
Class II · Moderate risk

Alcolado Relampago

CGMP Deviations: Products not manufactured under current good manufacturing practices.

Completed cGMP deviation Ecometics, Inc. D-1098-2023
Class II · Moderate risk

Yager's Liniment

CGMP Deviations: Products not manufactured under current good manufacturing practices.

Completed cGMP deviation Ecometics, Inc. D-1097-2023
Class II · Moderate risk

Blis-To-Sol Liquid

CGMP Deviations: Products not manufactured under current good manufacturing practices.

Completed cGMP deviation Ecometics, Inc. D-1096-2023
Class II · Moderate risk

Pantoprazole sodium for Injection 40 mg*/vial

CGMP Deviations; The impacted product and lot number was inadvertently placed into saleable inventory, which does not comply with approved procedures.

Completed cGMP deviation Methapharm Inc NDC 67850-150-10 D-0540-2023
Class II · Moderate risk

Triamcinolone Acetonide cream

CGMP Deviations: Product complaints reporting the product to have a gritty texture and lack of effectiveness.

Completed cGMP deviation Direct Rx NDC 72189-330-80 D-1535-2022
Class II · Moderate risk

Zonisamide Capsules

cGMP deviations

Completed cGMP deviation Glenmark Pharmaceuticals Inc., USA NDC 68462-130-01 D-0793-2022
Class II · Moderate risk

Zonisamide Capsules

cGMP deviations

Completed cGMP deviation Glenmark Pharmaceuticals Inc., USA NDC 68462-129-01 D-0792-2022

Recalls by year